EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Virax Biolabs Group's enterprise value is $-0.35 Mil.
Virax Biolabs Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-5.80 Mil. Therefore, Virax Biolabs Group's EV-to-EBITDA for today is 0.06.
The historical rank and industry rank for Virax Biolabs Group's EV-to-EBITDA or its related term are showing as below:
VRAX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -192.84 Med: 0.13 Max: 1.59
Current: 0.06
During the past 6 years, the highest EV-to-EBITDA of Virax Biolabs Group was 1.59. The lowest was -192.84. And the median was 0.13.
VRAX's EV-to-EBITDA is ranked better than 96.16% of 469
companies
in the Biotechnology industry
Industry Median: 9.99
vs VRAX: 0.06
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Virax Biolabs Group EV-to-EBITDA Historical Data
The historical data trend for Virax Biolabs Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Virax Biolabs Group's EV-to-EBITDA
For the Biotechnology subindustry, Virax Biolabs Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virax Biolabs Group's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Virax Biolabs Group's EV-to-EBITDA falls into.
Virax Biolabs Group's current Enterprise Value is $-0.35 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Virax Biolabs Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-5.80 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virax Biolabs Group (NAS:VRAX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Virax Biolabs Group's PE Ratio (TTM) for today is calculated as:
Virax Biolabs Group's share price for today is $0.8664.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Virax Biolabs Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.620.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Virax Biolabs Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VRAX has been successfully added to your 